Catalyst Event
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (6990) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
5/31/2026, 12:00:00 AM
The company announced on May 31, 2026, that its Phase III study (OptiTROP-Lung05) of sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab for first-line treatment of PD-L1 positive NSCLC met its primary endpoint.
Korean Translation
2026년 5월 31일 PD-L1 양성 비소세포폐암(NSCLC) 1차 치료를 위한 사시투주맙 티루모테칸(sac-TMT)과 펨브롤리주맙 병용 요법에 대한 3상 연구(OptiTROP-Lung05)가 1차 평가변수를 충족했다고 발표함.
Related Recent Events
Ambu A/S (AMBUB) · Earnings Release
Q3 2025/26 earnings release scheduled. (Low importance estimated for a routine scheduled event).
8/26/2026, 12:00:00 AM
Boston Scientific Corp (BSX) · Earnings Release
Q2 2026 earnings results and conference call for July 29, 2026, before market open scheduled
7/29/2026, 12:00:00 AM
Integer Holdings Corp (ITGR) · Earnings Release
Analysts forecast the next quarterly earnings release for 2026-07-23 estimated. Estimated Medium importance as earnings reports typically drive significant price volatility.
7/23/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
7/22/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Pharmaron Beijing Co Ltd (3759) · Other
The ex-dividend date for the RMB 0.20 per share final dividend on July 7, 2026, with payment on August 7, 2026; market reaction is estimated at Low as the payout is within expected ranges scheduled.
7/7/2026, 12:00:00 AM